New Medication for Early-Stage Non-small cell Lung Cancer Request More Information Trial Objective Researchers are testing a medication called atezolizumab and its effects on early-stage non-small cell lung cancer (NSCLC). Atezolizumab is an experimental immunotherapy medicine, which is a man-made antibody. Antibodies are used by the immune system to identify and destroy bacteria, viruses and tumor cells. Atezolizumab is approved to treat advanced cancer of the bladder and lung, and researchers believe it may help people who have early-stage NSCLC. In this study, participants will get either atezolizumab and chemotherapy or a placebo and chemotherapy before undergoing surgery to remove their tumor. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults diagnosed with early-stage non-small cell lung cancer (NSCLC) that can be surgically removed. Age: 18+ Gender: Any Gender Estimated Time Commitment The screening period may last up to 6 weeks and involve up to 2 visits to the clinic. One group will receive pre-surgery treatment for up to 12 weeks, then undergo surgery, followed by taking atezolizumab for up to 48 weeks. The other group will receive pre-surgery treatment for up to 12 weeks, undergo surgery and then be given the best supportive care and monitoring. Maximum of clinic visits would be once a week. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Not Provided Travel Reimbursement: Available Trial Contact For more information, contact: Jami Henriksen 303.398.1233 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors F. Hoffmann-La Roche Ltd Principal Investigators Laurie Carr, MD + × Laurie Carr, MD Associate Professor Department of Medicine Division of Oncology, Cancer Center View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Co-Investigators John Mitchell, MD + × John Mitchell, MD Thoracic Surgeon Professor Thoracic Surgery Clinic View Full Profile Make an Appoinment Rosane Duarte Achcar, MD, FCAP, FASCP + × Rosane Duarte Achcar, MD, FCAP, FASCP Pathologist Associate Professor Department of Medicine Division of Pathology View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Researchers are testing a medication called atezolizumab and its effects on early-stage non-small cell lung cancer (NSCLC). Atezolizumab is an experimental immunotherapy medicine, which is a man-made antibody. Antibodies are used by the immune system to identify and destroy bacteria, viruses and tumor cells. Atezolizumab is approved to treat advanced cancer of the bladder and lung, and researchers believe it may help people who have early-stage NSCLC. In this study, participants will get either atezolizumab and chemotherapy or a placebo and chemotherapy before undergoing surgery to remove their tumor.